The prognosis depends on the histologic type, stage, and treatment. Next: Background What to Read Next on Medscape Related Conditions and Diseases Diffuse Large B-Cell Lymphoma (Non-Hodgkin Lymphoma) Staging Non-Hodgkin Lymphoma Guidelines Cutaneous B-Cell Lymphoma Diffuse Large B-Cell ...
PROGNOSISBackground: Nodal small cell B‐cell lymphoma subtypes in dogs cannot be distinguished by flow cytometry and information regarding treatment, prognosis, and outcome are limited. Hypothesis/Objectives: Objectives were to describe outcome in dogs with nodal small cell B‐cell lymp...
The different types of B-cell non-Hodgkin’s lymphomas include diffuse large B-cell lymphoma (DLBCL), the most common non-Hodgkin’s lymphoma in the U.S., estimated by the American Cancer Society to be about one in every three cases; primary mediastinal (thymic) large B-cell lymphoma, a...
[6]Biojone E, Queiróz Rde P, Valera ET, et al. Minimal residual disease in cerebrospinal fluid at diagnosis: a more intensive treatment protocol was able to eliminate the adverse prognosis in children with acute lymphoblastic leukemia[J]. Leuk Lymphoma, 2012, 53(1):89-95. [7]Gao L, ...
To date, CD56 has not been detected in human primary B-cell neurolymphomatosis and further insight into the pathogenesis of primary B-cell neurolymphomatosis is required (Baehring et al., 2003). With respect to the biological importance of CD56, the previous studies of T- or NK-cell ...
B淋巴母细胞淋巴瘤是一类在儿童中发病率较高且易发生骨髓和中枢神经系统(Central nervous system, CNS)等部位侵犯的原始细胞淋巴瘤。由于CNS侵犯是影响患者预后的独立危险因素之一,及早发现并采取治疗措施尤为重要[1, 2]。2019年8月,我院儿科收治一例经病理检...
[G]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to ...
first in animal models and subsequently in clinical studies. In particular, the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with hi...
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignancy characterized by varied responses to treatment and prognoses. Understanding the metabolic characteristics driving DLBCL progression is crucial for developing personalized therapies. This
The molecular diversity exhibited by diffuse large B-cell lymphoma (DLBCL) is a significant obstacle facing current precision therapies. However, scoring using the International Prognostic Index (IPI) is inadequate when fully predicting the development of DLBCL. Reprogramming lipid metabolism is crucial ...